drugset / Trial / NCT00236613
A Study on Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to compare the safety and effectiveness of topiramate (64mg, 96mg, 192mg, and 384mg daily) with placebo in the treatment of obesity.
Timeline
- Start
- 2000-09
- Primary completion
- —
- Completion
- 2001-07
Outcome
Met primary endpoint
paper DISCUSSION: TPM produced significantly greater weight loss than placebo at all doses. PMID 12805393 ↗
Publications
- Results Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M, Perry BH. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res. 2003 Jun;11(6):722-33. doi: 10.1038/oby.2003.102.
- Loring DW, Williamson DJ, Meador KJ, Wiegand F, Hulihan J. Topiramate dose effects on cognition: a randomized double-blind study. Neurology. 2011 Jan 11;76(2):131-7. doi: 10.1212/WNL.0b013e318206ca02. Epub 2010 Dec 9.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Topiramate | Small molecule | 64 mg | Oral |
| Subject | Topiramate | Small molecule | 96 mg | Oral |
| Subject | Topiramate | Small molecule | 192 mg | Oral |
| Subject | Topiramate | Small molecule | 384 mg | Oral |